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Project Introduction
Spaceflight perturbs the human immune system. Among other manifestations,
crewmembers may experience latent herpesviruses reactivation due to impaired
lymphocyte function, as well as allergic/hypersensitivity reactions. Considering
future space travel will be of longer duration (thereby increasing stress,
exposure to radiation, etc…) with no rapid return option, it is of paramount
importance to develop a countermeasure(s) to immune dysregulation.
Monophosphoryl lipid A (MPLA) is a derivative of lipopolysaccharide (LPS), a
potent inflammatory agent that can cause septic shock. MPLA possesses the
immune-stimulatory effects of LPS without the adverse inflammatory effects.
We hypothesize that treating immune cells with MPLA will boost their function
enough to overcome the inhibitory effects of microgravity. While MPLA has been
tested as an adjuvant extensively in mice and preliminarily for human vaccines,
it has never been assessed for efficacy in microgravity.
Anticipated Beneﬁts
An emerging paradigm in spaceflight immunology is a direct correlation between
the amount of time spent in microgravity, the degree of immune system
dysregulation, and the incidence of clinical sequelae. Given the next NASA
objective is voyage beyond lower-Earth orbit -- and missions of
unprecedented duration – it is reasonable to hypothesize the clinical risk to
astronauts will be higher than ever before. Thus, our communal goal is to
ensure the health and safety of prospective crewmembers. To this end, we
must identify a set of countermeasures, offering broad coverage, that will
obviate any clinical risks. This project leverages the validated cell culture
techniques and immune measures of the JSC Immunology Laboratory, as well
as the ground-based microgravity cell culture analog (‘Clinostat’) available in the
laboratory, to define an innovative experimental approach to evaluate candidate
immune countermeasures. MPLA is the first of a suite of compounds we will
test.
Project Closeout - Executive Summary
We cultured immune cells in either static (1xG) or microgravity/clino-rotation
conditions, with or without stimuli to induce cellular activation, and with or
without the MPLA compound countermeasure. Using our standard measures of
immune competency via multi-parametric flow cytometry, we expected to
observe a normal robust response, the suppressive effects of microgravity
culture, and the restorative effects of MPLA as a countermeasure.
Unfortunately, MPLA treatment did not recover 6-hour cytokine production by T
cells, nor their activation status after 24-hour stimulation, that were lost in the
clinostat representing microgravity. While MPLA was not able to prevent T cell
impairment, its mechanism of action suggests it will be effective at boosting the
function of other immune cells; we will test its effect on monocytes and natural
killer (NK) cells. Broadly, this project proves our laboratory method is optimal;
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we are prepared to evaluate a suite of immune dysfunction countermeasure
products. Once we identify an immune countermeasure in this setting, our goal
is to perform similar assessments in a ground analog, such as Antarctica
Winter-over, and ultimately with crewmembers onboard ISS.
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